Anzeige
Mehr »
Login
Dienstag, 28.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PD18 | ISIN: KYG283651076 | Ticker-Symbol:
NASDAQ
27.01.25
21:40 Uhr
1,640 US-Dollar
+0,050
+3,14 %
Branche
Finanzdienstleistungen
Aktienmarkt
ASIEN
1-Jahres-Chart
METALPHA TECHNOLOGY HOLDING LIMITED Chart 1 Jahr
5-Tage-Chart
METALPHA TECHNOLOGY HOLDING LIMITED 5-Tage-Chart
PR Newswire
211 Leser
Artikel bewerten:
(1)

Metalpha Technology Holding Limited: Metalpha Receives Notification of Deficiency from The Nasdaq Stock Market LLC

Finanznachrichten News

HONG KONG, Aug. 19, 2024 /PRNewswire/ -- Metalpha Technology Holding Limited (Nasdaq: MATH) (the "Company" or "Metalpha"), a global digital asset-focused wealth management company, today announced that on August 1 5, 202 4 it has received a written notice from The Nasdaq Stock Market LLC (the "Nasdaq") which states that, as a result of not having timely filed its annual report on Form 20-F for the fiscal year ended March 31, 202 4 (the "202 4 Form 20-F "), Metalpha is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the "SEC"). This notice has no immediate effect on the listing or trading of Metalpha's ordinary shares on the Nasdaq Capital Market.

The Company is required by Nasdaq to submit its plan to regain compliance within 60 calendar days, or no later than October 1 4, 202 4 . If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the 202 4 Form 20-F's due date, or until February 1 0, 202 5, to regain compliance.

The Company was not able to file the 202 4 Form 20-F by its due date primarily due to the additional time needed to prepare the 202 4 Form 20-F, as set forth in the Form 12b-25 submitted to the SEC on July 31, 202 4 . Metalpha continues to work diligently to complete the 202 4 Form 20-F and strives to file it with the SEC as soon as reasonably practicable.

About Metalpha Technology Holding Limited

Founded in 2015, Metalpha Technology Holding Limited (Nasdaq: MATH) went public on October 20, 2017. The listed Company, through its subsidiaries, is dedicated to providing investing and wealth management services with a full-service, institutional-grade platform. With dedicated blockchain expertise, the Company aims to become a leader in the field of crypto wealth management services, bringing robust innovation and transparency to the customers and businesses it serves.

Forward-Looking Statement s

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management's control. These statements involve risks and uncertainties that may cause Metalpha's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

SOURCE Metalpha Technology Holding Limited

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.